DK2055711T3 - Anvendelse af squalensyre til formulering af et aktivt stof i nanopartikeltilstand - Google Patents
Anvendelse af squalensyre til formulering af et aktivt stof i nanopartikeltilstandInfo
- Publication number
- DK2055711T3 DK2055711T3 DK09152764.8T DK09152764T DK2055711T3 DK 2055711 T3 DK2055711 T3 DK 2055711T3 DK 09152764 T DK09152764 T DK 09152764T DK 2055711 T3 DK2055711 T3 DK 2055711T3
- Authority
- DK
- Denmark
- Prior art keywords
- formulation
- active substance
- derivatives
- difluoro
- nanoparticles
- Prior art date
Links
- 239000002105 nanoparticle Substances 0.000 title abstract 5
- 239000002253 acid Substances 0.000 title abstract 2
- 239000013543 active substance Substances 0.000 title abstract 2
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 title 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 title 1
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 title 1
- 238000009472 formulation Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 229940031439 squalene Drugs 0.000 title 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 title 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 2
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical class O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- 230000030833 cell death Effects 0.000 abstract 1
- 239000000824 cytostatic agent Substances 0.000 abstract 1
- 230000001085 cytostatic effect Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000010534 mechanism of action Effects 0.000 abstract 1
- 239000002798 polar solvent Substances 0.000 abstract 1
- 230000003362 replicative effect Effects 0.000 abstract 1
- 235000011178 triphosphate Nutrition 0.000 abstract 1
- 239000001226 triphosphate Substances 0.000 abstract 1
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 abstract 1
- 239000012873 virucide Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y30/00—Nanotechnology for materials or surface science, e.g. nanocomposites
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/073—Pyrimidine radicals with 2-deoxyribosyl as the saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Nanotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Condensed Matter Physics & Semiconductors (AREA)
- Composite Materials (AREA)
- Physics & Mathematics (AREA)
- Materials Engineering (AREA)
- Crystallography & Structural Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Saccharide Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0451365A FR2874016B1 (fr) | 2004-06-30 | 2004-06-30 | Nanoparticules de derives de la gemcitabine |
| EP05857322A EP1761551B1 (fr) | 2004-06-30 | 2005-06-23 | Nanoparticules de derives de la gemcitabine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2055711T3 true DK2055711T3 (da) | 2011-12-12 |
Family
ID=34945701
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK09152764.8T DK2055711T3 (da) | 2004-06-30 | 2005-06-23 | Anvendelse af squalensyre til formulering af et aktivt stof i nanopartikeltilstand |
| DK05857322.1T DK1761551T3 (da) | 2004-06-30 | 2005-06-23 | Nanopartikler af gemcitabinderivater |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK05857322.1T DK1761551T3 (da) | 2004-06-30 | 2005-06-23 | Nanopartikler af gemcitabinderivater |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US7704972B2 (da) |
| EP (3) | EP1761551B1 (da) |
| JP (2) | JP4927726B2 (da) |
| CN (2) | CN101061131B (da) |
| AT (2) | ATE520703T1 (da) |
| CA (2) | CA2572380C (da) |
| DK (2) | DK2055711T3 (da) |
| ES (2) | ES2371411T3 (da) |
| FR (1) | FR2874016B1 (da) |
| PT (2) | PT1761551E (da) |
| WO (1) | WO2006090029A1 (da) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2648099C (en) * | 2006-03-31 | 2012-05-29 | The Brigham And Women's Hospital, Inc | System for targeted delivery of therapeutic agents |
| FR2924024B1 (fr) * | 2007-11-27 | 2012-08-17 | Centre Nat Rech Scient | Nanoparticules d'actifs therapeutiques de faible solubilite aqueuse |
| FR2931152B1 (fr) * | 2008-05-16 | 2010-07-30 | Centre Nat Rech Scient | Nouveau systeme de transfert d'acide nucleique |
| WO2010039039A1 (en) * | 2008-10-03 | 2010-04-08 | Clavis Pharma Asa | Oral formulations of gemcitabine derivatives |
| FR2937537A1 (fr) * | 2008-10-29 | 2010-04-30 | Centre Nat Rech Scient | Nanoparticules de statine |
| FR2937549B1 (fr) * | 2008-10-29 | 2011-04-01 | Centre Nat Rech Scient | Nanoparticules de derives beta-lactamine |
| US9517476B2 (en) * | 2008-10-31 | 2016-12-13 | Hitachi Koki Co., Ltd. | Centrifuge with acceleration and deceleration time display |
| EP2393472B1 (en) | 2008-12-05 | 2019-06-05 | NanoMed Holdings Pty Ltd | Amphiphile prodrugs |
| FR2968662B1 (fr) | 2010-12-10 | 2013-11-22 | Roussy Inst Gustave | Nouveaux derives d'oxazaphosphorines pre-activees, utilisation et methode de preparation |
| US9693957B2 (en) | 2011-07-08 | 2017-07-04 | The University Of North Carolina At Chapel Hill | Metal bisphosphonate nanoparticles for anti-cancer therapy and imaging and for treating bone disorders |
| FR2988092B1 (fr) * | 2012-03-16 | 2014-04-25 | Centre Nat Rech Scient | Complexes de vitamine c, nanoparticules desdits complexes, procedes pour leur preparation, leurs compositions, leurs utilisations cosmetiques et procede de traitement cosmetique |
| SG11201503773SA (en) | 2012-11-13 | 2015-06-29 | Boyen Therapeutics Inc | Gemcitabine prodrugs and uses thereof |
| EP2742955A1 (en) | 2012-12-12 | 2014-06-18 | Centre National De La Recherche Scientifique | Nanoparticles based on bioconjugate of GAG |
| JP6083770B2 (ja) * | 2013-09-13 | 2017-02-22 | 板井 昭子 | 水溶液製剤及びその製造方法 |
| JP6590802B2 (ja) | 2013-11-06 | 2019-10-16 | ザ ユニバーシティ オブ シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ | 化学療法用薬剤、核酸及び光増感剤の送達又は共送達のためのナノスケール輸送体 |
| CN103599073A (zh) * | 2013-11-15 | 2014-02-26 | 无锡中科光远生物材料有限公司 | 一种负载有靶向抗癌药物的plga微米颗粒的制备方法 |
| WO2015081867A1 (zh) * | 2013-12-04 | 2015-06-11 | 杭州民生药物研究院有限公司 | 吉西他滨衍生物、含该衍生物的组合物及所述衍生物的制药用途 |
| US10463684B2 (en) | 2014-01-29 | 2019-11-05 | Board Of Regents, The Uneversety Of Texas System | Nucleobase analogue derivatives and their applications |
| CN105030682B (zh) * | 2015-06-24 | 2018-02-09 | 广州复大医疗股份有限公司 | 一种纳米微粒胶体及其制备方法与用途 |
| JP7090034B2 (ja) | 2016-05-20 | 2022-06-23 | ザ ユニバーシティ オブ シカゴ | 化学療法、標的療法、光線力学療法、免疫療法及びそれらの任意の組み合わせのためのナノ粒子 |
| TWI719182B (zh) * | 2017-03-29 | 2021-02-21 | 國立交通大學 | 奈米組成物、其製造方法及其用途 |
| US11306111B2 (en) | 2017-07-31 | 2022-04-19 | January Therapeutics, Inc. | Organophosphate derivatives |
| EP3638367A4 (en) | 2017-08-02 | 2021-07-21 | The University of Chicago | NANOMETRIC ORGANOMETALLIC AND NANOPLAQUE ORGANOMETALLIC LAYERS FOR X-RAY INDUCED PHOTODYNAMIC THERAPY, RADIOTHERAPY, RADIODYNAMIC THERAPY, CHEMOTHERAPY, IMMUNOTHERAPY, AND ANY COMBINATION OF THESE |
| JP2021516227A (ja) * | 2018-03-02 | 2021-07-01 | ジャニュアリー セラピューティクス，インク． | ナノ粒子組成物 |
| WO2019204869A1 (en) * | 2018-04-26 | 2019-10-31 | NanoMed Holdings Pty Ltd | Gemcitabine amphiphile prodrugs |
| EP3628735A1 (en) | 2018-09-25 | 2020-04-01 | Centre National De La Recherche Scientifique | Antisense rna targeting pmp22 for the treatment of charcot-marie-tooth 1a disease |
| CN114144187A (zh) * | 2019-06-06 | 2022-03-04 | 德克萨斯大学系统董事会 | 含有药物药剂和/或营养药剂的脂质纳米颗粒及其方法 |
| US11708637B2 (en) | 2019-08-13 | 2023-07-25 | The Regents Of The University Of California | Methods of supporting a graphene sheet disposed on a frame support |
| FR3110427B1 (fr) | 2020-05-20 | 2023-07-14 | Laboratoires Eriger | Conjugué terpenique de couplage |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9307043D0 (en) * | 1993-04-05 | 1993-05-26 | Norsk Hydro As | Chemical compounds |
| DE69812934T2 (de) * | 1997-01-24 | 2004-01-29 | Conpharma As Oslo | Gemcitabin-derivate |
| FR2808691B1 (fr) * | 2000-05-12 | 2005-06-24 | Coletica | Cyclodextrines substituees preferentiellement sur leur face primaire par des fonctions acide ou amine |
-
2004
- 2004-06-30 FR FR0451365A patent/FR2874016B1/fr active Active
-
2005
- 2005-06-23 EP EP05857322A patent/EP1761551B1/fr active Active
- 2005-06-23 CN CN2005800218778A patent/CN101061131B/zh active Active
- 2005-06-23 EP EP08100379A patent/EP1925624A1/fr not_active Withdrawn
- 2005-06-23 CA CA2572380A patent/CA2572380C/fr active Active
- 2005-06-23 EP EP09152764A patent/EP2055711B1/fr active Active
- 2005-06-23 US US11/631,075 patent/US7704972B2/en active Active
- 2005-06-23 DK DK09152764.8T patent/DK2055711T3/da active
- 2005-06-23 AT AT09152764T patent/ATE520703T1/de active
- 2005-06-23 DK DK05857322.1T patent/DK1761551T3/da active
- 2005-06-23 JP JP2007518660A patent/JP4927726B2/ja active Active
- 2005-06-23 PT PT05857322T patent/PT1761551E/pt unknown
- 2005-06-23 CN CN201110251937.2A patent/CN102335436B/zh active Active
- 2005-06-23 AT AT05857322T patent/ATE519773T1/de active
- 2005-06-23 ES ES05857322T patent/ES2371411T3/es active Active
- 2005-06-23 CA CA2805761A patent/CA2805761C/fr active Active
- 2005-06-23 ES ES09152764T patent/ES2372141T3/es active Active
- 2005-06-23 WO PCT/FR2005/050488 patent/WO2006090029A1/fr active Application Filing
- 2005-06-23 PT PT09152764T patent/PT2055711E/pt unknown
-
2010
- 2010-03-04 US US12/717,639 patent/US8044034B2/en active Active
-
2011
- 2011-12-07 JP JP2011267891A patent/JP5552473B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN102335436B (zh) | 2014-10-08 |
| JP4927726B2 (ja) | 2012-05-09 |
| JP2008504353A (ja) | 2008-02-14 |
| CA2572380A1 (fr) | 2006-08-31 |
| CA2805761C (fr) | 2016-10-04 |
| EP1925624A1 (fr) | 2008-05-28 |
| US8044034B2 (en) | 2011-10-25 |
| DK1761551T3 (da) | 2011-11-28 |
| ATE520703T1 (de) | 2011-09-15 |
| CN101061131B (zh) | 2011-10-05 |
| EP2055711B1 (fr) | 2011-08-17 |
| JP2012102107A (ja) | 2012-05-31 |
| FR2874016A1 (fr) | 2006-02-10 |
| US20100160249A1 (en) | 2010-06-24 |
| EP1761551B1 (fr) | 2011-08-10 |
| PT1761551E (pt) | 2011-11-24 |
| PT2055711E (pt) | 2011-12-07 |
| ES2371411T3 (es) | 2012-01-02 |
| CA2805761A1 (fr) | 2006-08-31 |
| CN102335436A (zh) | 2012-02-01 |
| JP5552473B2 (ja) | 2014-07-16 |
| EP1761551A1 (fr) | 2007-03-14 |
| FR2874016B1 (fr) | 2006-11-24 |
| CN101061131A (zh) | 2007-10-24 |
| ES2372141T3 (es) | 2012-01-16 |
| EP2055711A1 (fr) | 2009-05-06 |
| ATE519773T1 (de) | 2011-08-15 |
| WO2006090029A1 (fr) | 2006-08-31 |
| US7704972B2 (en) | 2010-04-27 |
| CA2572380C (fr) | 2013-11-19 |
| US20090130214A1 (en) | 2009-05-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2055711T3 (da) | Anvendelse af squalensyre til formulering af et aktivt stof i nanopartikeltilstand | |
| Gilad et al. | Accelerated functional recovery and neuroprotection by agmatine after spinal cord ischemia in rats | |
| NO20071853L (no) | Farmasoytisk sammensetning inneholdende en fast dispersjon med en polymermatriks inneholdende en jevn polydekstrosefase og en jevn fase av en polymer forskjellig fra polydekstrose. | |
| CR7718A (es) | Nuevos derivados de glicosido de tiofeno, metodos para la preparacion de los mismos, medicamentos que comprenden dichos compuestos, y su uso | |
| CY1112831T1 (el) | Παραγωγα αζαβιρηενυlαμινοβενζοιc acid σαν παραγοντες καταστολης dhodh | |
| BR0307117A (pt) | Amidas de ácido antranìlico e seus derivados como compostos ativos cosméticos e farmacêuticos | |
| DOP2010000114A (es) | Producto de dispersion solida que contiene un compuesto a base de n-aril urea | |
| JP2003503348A5 (da) | ||
| BG105654A (en) | Telmisartan polymorphs, methods for producing same and their use in the preparation of a medicament | |
| MX2012000414A (es) | Derivados piridin-4-ilo. | |
| Morello et al. | Vasorelaxant effect of the flavonoid galangin on isolated rat thoracic aorta | |
| RU2012127776A (ru) | Растворимые пленки, содержащие высокие концентрации неионных поверхностно-активных веществ, таких как полисорбаты, для увеличения высоких нагрузок твердых продуктов | |
| CY1110037T1 (el) | Σκευασματα για βενζιμιδαζολυλ πυριδυλ αιθερες | |
| WO2012073170A3 (fr) | Composition galénique adaptée à l'administration à un animal non-humain, utilisations de celle-ci et méthodes associées | |
| DOP2010000374A (es) | Derivados heterociclicos de la urea y sus metodos de empleo | |
| ES2054949T3 (es) | Precursores de dopamina. | |
| WO2007119001A3 (fr) | Derives d 'aminomethyl pyridine, leur preparation et leur application en therapeutique | |
| SE0302573D0 (sv) | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof | |
| UY29892A1 (es) | Nuevos derivados de cromano, composiciones farmaceuticas conteniendolos, procesos de preparacion y aplicaciones | |
| RU2008110644A (ru) | Применение производных глутаровой кислоты или их фармацевтически приемлемых солей в качестве противоаритмических средств | |
| SE0302570D0 (sv) | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof | |
| JP2012528801A5 (da) | ||
| SE0302572D0 (sv) | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof | |
| BR0307913A (pt) | Uso de uma composição, composição farmacêutica para administração nasal, e, métodos para eliciar um efeito terapêutico, profilático e/ou diagnóstico em um mamìfero, para obter um inìcio rápido de um efeito terapêutico, profilático e/ou diagnóstico de uma substância ativa em um mamìfero e para melhorar a biodisponibilidade de um efeito terapêutico, profilático e/ou diagnóstico de uma substância ativa em um mamìfero | |
| Chhikara et al. | N-Myristoylglutamic acid derivative of 3′-fluoro-3′-deoxythymidine as an organogel |